Concert Pharmaceuticals could earn about $120 million in milestone payments plus tiered royalties under Jazz Pharmaceuticals' exclusive license to Concert's deuterium-modified compounds containing sodium oxybate, the active ingredient in Jazz's narcolepsy drug Xyrem.
CEO Roger Tung of Lexington, Massachusetts-based Concert could not disclose the upfront payment from Jazz, but he told Scrip that royalties under the companies' agreement will go as high as...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?